Bottom line
Is LFSC a good fund? The bottom line
LFSC is a managed technology sector ETF from Rbb.
It charges 0.54% — about $54 a year on every $10,000 invested, cheaper than 75% of technology sector funds we track.
With $105 million in net assets and 40 holdings, its largest position is Travere Therapeutics Inc (7.7%) and the top 10 make up 54.7% of the portfolio.
What stands out
- Low cost: cheaper than 75% of technology sector peers
What to watch
- Concentrated: top 10 holdings are 54.7% of assets
Updated Nov 19, 2026
What LFSC invests in
The investment objective of the F/m Emerald Life Sciences Innovation ETF (the Fund) is to seek long-term capital appreciation.
The Fund is an actively managed exchange-traded fund (ETF) and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust (the Sub-Adviser), the Funds investment sub-adviser, under the supervision of the Adviser. The Fund intends to identify and invest in unique growth opportunities within the life sciences universe by following scientific, technological and/or strategic innovation. The Sub-Adviser believes that innovative companies are those developing new products or reinventing/redesigning existing products/services, thereby generating value for their customers, creating a competitive advantage and/or driving business growth. The Sub-Adviser applies this theme of innovation by using its proprietary 10-step research process to identify companies that the Sub-Adviser believes are substantially focused on or are expected to…
From the fund's prospectus (filed Jan 5, 2026).
What LFSC costs
On a $10,000 investment, LFSC's 0.54% expense ratio costs about $54 a year. The prospectus estimates $955 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
LFSC top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Travere Therapeutics Inc TVTX | 7.67% |
| 2 | Cogent Biosciences Inc COGT | 7.53% |
| 3 | LivaNova PLC LIVN | 7.11% |
| 4 | Spyre Therapeutics Inc SYRE | 6.41% |
| 5 | Guardant Health Inc GH | 5.52% |
| 6 | Mirum Pharmaceuticals Inc MIRM | 4.92% |
| 7 | Corcept Therapeutics Inc CORT | 4.79% |
| 8 | United Therapeutics Corp UTHR | 4.16% |
| 9 | VeraDermics Inc MANE | 3.42% |
| 10 | Savara Inc SVRA | 3.22% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 54.7% of the fund. See all top 25 holdings and asset mix →